LnclIRS1 controls muscle atrophy via sponging miR-15 family to activate IGF1-PI3K/AKT pathway

Zhenhui Li¹, Bolin Cai¹, Bahareldin Ali Abdalla¹,², Xuenong Zhu¹,²,³, Ming Zheng¹,², Peigong Han¹,², Qinghua Nie¹,²* & Xiquan Zhang¹,²

¹Department of Animal Genetics, Breeding and Reproduction, College of Animal Science, South China Agricultural University, Guangzhou 510642, Guangdong, China, ²Guangdong Provincial Key Lab of Agro-Animal Genomics and Molecular Breeding, and Key Laboratory of Chicken Genetics, Breeding and Reproduction, Ministry of Agriculture, Guangzhou, Guangdong, China, ³Institute of Biotechnology, Nanchang Normal University, Nanchang 330032, Jiangxi, China

Abstract

**Background** Recent studies indicate important roles for long noncoding RNAs (lncRNAs) in the regulation of gene expression by acting as competing endogenous RNAs (ceRNAs). However, the specific role of lncRNAs in skeletal muscle atrophy is still unclear. Our study aimed to identify the function of lncRNAs that control skeletal muscle myogenesis and atrophy.

**Methods** RNA sequencing was performed to identify the skeletal muscle transcriptome (lncRNA and messenger RNA) between hypertrophic broilers and leaner broilers. To study the ‘sponge’ function of lncRNA, we constructed a lncRNA-microRNA (miRNA)-gene interaction network by integrated our previous submitted skeletal muscle miRNA sequencing data. The primary myoblast cells and animal model were used to assess the biological function of the LnclIRS1 in vitro or in vivo.

**Results** We constructed a myogenesis-associated lncRNA-miRNA-gene network and identified a novel ceRNA lncRNA named LnclIRS1 that is specifically enriched in skeletal muscle. LnclIRS1 could regulate myoblast proliferation and differentiation in vitro, and muscle mass and mean muscle fibre in vivo. LnclIRS1 increases gradually during myogenic differentiation. Mechanistically, LnclIRS1 acts as a ceRNA for miR-15a, miR-15b-5p, and miR-15c-5p to regulate IRS1 expression, which is the downstream of the IGF1 receptor. Overexpression of LnclIRS1 not only increased the protein abundance of IRS1 but also promoted phosphorylation level of AKT (p-AKT) a central component of insulin-like growth factor-1 pathway. Furthermore, LnclIRS1 regulates the expression of atrophy-related genes and can rescue muscle atrophy.

**Conclusions** The newly identified LnclIRS1 acts as a sponge for miR-15 family to regulate IRS1 expression, resulting in promoting skeletal muscle myogenesis and controlling atrophy.

**Keywords** Atrophy; ceRNA; IRS1; Myogenesis; lncRNA-miRNA-gene network

Received: 23 July 2018; Accepted: 12 November 2018

*Correspondence to: Qinghua Nie, Department of Animal Genetics, Breeding and Reproduction, College of Animal Science, South China Agricultural University, Guangzhou 510642, Guangdong, China. Tel: 86-20-85285759, Fax: 86-20-85280740, Email: nqinghua@scau.edu.cn

**Introduction**

A decrease in adult muscle mass and fibre size is called ‘atrophy’ and is characterized by enhanced protein degradation.²⁻³ An increase in muscle mass, called ‘hypertrophy’, is associated with increased protein synthesis.³ Therefore, the maintenance of muscle mass is controlled through a balance between protein synthesis and protein degradation.

**Abbreviations**

- miRNA – microRNA
- lncRNAs – long noncoding RNAs
- CCK-8 – cell counting kit-8
- NC – negative control
- ceRNA – competing endogenous RNA
- MREs – miRNA response elements
- IPA – ingenuity pathway analysis
- EdU – 5-ethynyl-2’-deoxyuridine

© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
pathways. Skeletal muscle atrophy occurs in a variety of conditions, such as cancer cachexia, prolonged periods of muscle inactivity, and aging itself. Unfortunately, there are no effective pharmacological treatments for this devastating disease.

Skeletal muscle myogenesis and hypertrophy is a multistep process that comprises four major stages: in the initial stage, muscle precursor cells differentiate from the somite; in the second stage, myogenic precursor proliferation and differentiation gives rise to myoblasts; in the third stage, myoblast differentiation gives rise to myotubes; and finally, myofibers are formed from the myotubes. These complex cellular and development processes depend on the precise spatiotemporal expression of regulatory factors. Insulin receptor substrate 1 (IRS1) is a signalling adapter protein, essential for skeletal muscle growth and protein homeostasis. Mice lacking IRS1 have reduced growth rate by 40–70% compared to controls. IRS1 plays a key role in transmitting signals from the insulin and insulin-like growth factor-1 (IGF-1) receptors to intracellular signalling pathway PI3K/AKT. IGF1-PI3K/AKT pathway is a key intracellular signalling mechanism controlling muscle hypertrophy. In addition, evidence suggests that in complex organism development, RNA contains a hidden layer of regulatory information. It not only functions as a messenger between DNA and the protein but also plays a role in the modulation of gene expression. Long noncoding RNAs (lncRNAs), a novel class of regulatory RNAs, commonly defined as transcribed RNAs with sizes ranging from 200 bp to >100 kb, are involved in numerous important biological processes. For example, SRA, a lncRNA, was demonstrated to facilitate myoblast differentiation by controlling the transcriptional activity of MyoD. Salmenna previously presented a competing endogenous RNA (ceRNA) hypothesis that was supported by many evidences. LncRNAs can function as ceRNAs protect messenger RNAs (mRNAs) by acting as molecular sponges for microRNAs (miRNAs) that specifically inhibit the target mRNAs (Figure S1). For example, Linc-MD1 acts as a ceRNA by sponging miR-133 and miR-135 to regulate the expression of MAML1 and MEF2C, which are transcription factors that activate late-differentiation muscle genes. In addition, IncRNA H19, which is highly expressed in the developing embryo and in adult muscle, functions as a molecular sponge for the let-7 family and thereby regulates muscle differentiation. Although functions of these IncRNAs have been partially characterized, most of their roles for myogenesis and anti-atrophy are still poorly understood. Therefore, the aim of our study is to explore the role of IncRNAs in regulating of skeletal muscle myogenesis and anti-atrophy.

In this study, we first focused on skeletal muscle myogenesis associated-lncRNAs and constructed a ceRNA network (lncRNA-miRNA-gene network) in silico. We investigated the function of a novel IncRNA named LncIRS1 in skeletal muscle myogenesis. LncIRS1 was highly expressed in skeletal muscle and promoted proliferation and differentiation of myoblast. Mechanistic investigations showed that LncIRS1 functioned as a ceRNA by sponging miR-15a, miR-15b-5p, and miR-15c-5p, which then activated IRS1 and regulated the IGF-1 signalling pathway, a critical pathway of skeletal muscle myogenesis. Moreover, the effect of LncIRS1 overexpression and knockdown on skeletal muscle atrophy induced by dexamethasone was investigated. Our study provides some clues regarding LncIRS1 mechanism of regulation in skeletal muscle myogenesis and atrophy.

### Material and methods

#### Animals

Seven-week-old of hypertrophic (WRR) and leaner broilers (XH) were used. All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

#### RNA sequencing (RNA-Seq)

Breast muscle tissues from WRR and XH broilers were used for RNA-seq. Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. RNA quantity and quality were evaluated on an Agilent 2100 Bioanalyzer (Agilent technologies, Waldbronn, Germany), and RNA integrity was further examined using agarose gel electrophoresis. Ribosomal RNA (rRNA) was removed from the total RNA using Epicentre Ribo-ZeroTM rRNA Removal Kit (Epicentre, Madison, Wisconsin, USA) following the manufacturer’s instructions. Subsequently, the RNA from four broilers within each group was mixed in equal amounts to construct a pooled sample for each group. High-throughput RNA-seq was performed on the Illumina Hiseq 2000 platform (Illumina, San Diego, CA, USA). The raw Illumina sequencing reads were cleaned by removing empty reads, adapter sequences, reads with over 10% N sequence, and low-quality reads in which the number of bases with a quality value Q ≤ 10 was greater than 50%. In addition, rRNA reads were identified by blasting against the rRNA database (http://www.arb-silva.de/) using SOAP software and removed from the dataset. The filtered reads were mapped to the chicken reference genome (ftp://ftpensembl.org/pub/release-73/fasta/gallus_gallus/dna/) using TopHat2. The mapped reads were assembled and transcripts were constructed using Cufflinks 2.0.2. The Ensembl, NCBI RefGene, and UCSC databases were chosen as annotation references for IncRNA analyses. RNA length ≥ 200 nt, CPC score ≤ 0, CPAT probability ≤ 0.364, and phyloCSF score ≤ −20 were used to evaluate the coding potential of transcripts. The RefSeq and Ensembl databases were used for gene analysis.

Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 391–410

DOI: 10.1002/jcsm.12374
The expression levels of the transcripts are expressed as fragments per kilobase of transcript per million mapped reads values. Differentially expressed transcripts for were identified using Cuffdiff, using q-value <0.001 and |(fold change)| ≥ 2 as the cut-off. The sequencing data obtained from the RNA-Seq were released to the GEO database under accession number GSE58755.

Construction of IncRNA-miRNA-gene interaction network

Previous study proposed a ceRNA hypothesis that protein-coding RNAs and IncRNAs containing the common one or more miRNA response elements (MREs) can compete for binding to miRNAs and regulate each other’s expression. To study the ‘sponge’ function of IncRNA, we constructed a IncRNA-miRNA-gene interaction network by integrated our previous submitted skeletal muscle miRNA sequencing data (GSE62971). The IncRNA-miRNA-gene crosstalk network construction involved the following three components: (i) interactions between miRNAs and genes, (ii) interactions between IncRNAs and miRNAs, and (iii) interaction between genes and IncRNAs. Firstly, the potential target genes of differentially expressed miRNAs were predicted with TargetScan; miRNAs repress their target genes expression at post-transcriptional level. Therefore, the predicted target genes that have an opposition expression patterns of their corresponding miRNAs were selected as candidate targets for differentially expressed miRNAs. Secondly, RNAhybrid, a tool for finding the minimum free energy hybridization of a long and a short RNA, was used to predict the target IncRNA of differentially expressed miRNA. As miRNA can repress the expression of mRNA, it also can inhibit the expression of its target IncRNAs. Therefore, the predicted target IncRNAs that have an opposition expression patterns of their corresponding miRNAs were selected as candidate target IncRNAs for differentially expressed miRNAs. Thirdly, ingenuity pathway analysis (IPA), a database of known and predicted protein interactions, was used to construct gene–gene interactions. Finally, IncRNA-miRNA-mRNA interaction network was constructed using Cytoscape. The Molecule Annotation System 3.0 (http://bioinfo.capitalbio.com/mas3) was used to identify GO terms and pathways enriched in genes belonging to IncRNA-miRNA-gene interaction network.

In situ hybridization

Whole-mount in situ hybridization of chick embryos was performed according to a standard in situ hybridization protocol. Digoxigenin-labelled probes were synthesized to detect IRS1 and LncIRS1. IRS1: Forward: ACCTGGAGCTTGTTG AAGGATTGC; Reverse: ATTAACCCCTACTAAAGGGA GACCCA TTTACAGGAAGAGGAGGAG. LncIRS1: Forward: GTATTG GTCA CTCGGTCAG; Reverse: AATTAACCTCACTAAAGGGA GACCTTCATTT CCCTTGGGTA. The whole embryos at stage HH10 were fixed with 4% paraformaldehyde overnight at 4°C, dehydrated in a graded series of methanol, and stored at −20°C (overnight). Next, the embryos were hybridized with IRS1 or LncIRS1 digoxigenin-labelled probe overnight at 65°C. After hybridization, the bound RNA probe was visualized by incubation with alkaline phosphatase-conjugated anti-digoxigenin antibodies, and the colour was developed in NBT/BCIP (Roche, Basel, Switzerland). The whole-mount stained embryos were photographed under a stereomicroscope (Olympus MVX10).

Cell culture, treatment, and transfection

Chicken embryonic fibroblast cell line (DF-1 cells) were cultivated with Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY, USA) supplemented with 10% foetal bovine serum (Gibco) and 0.2% penicillin/streptomycin (Gibco) in a humidified atmosphere with 5% (v/v) CO2 at 37°C. Chicken primary myoblasts were isolated from E11 chicken leg muscles as previously described. Chicken primary myoblasts were cultured with growth medium consisting of RPMI-1640 medium (Gibco), 20% foetal bovine serum, and 0.2% penicillin/streptomycin. After myoblasts achieving 100% cell confluence, the growth medium was then removed and replaced with differentiation medium (RPMI-1640 medium, 2% horse serum and 0.2% penicillin/streptomycin). For cell treatments, myotubes were treated with vehicle and 10 μM dexamethasone (Sigma-Aldrich, St. Louis, Mo, USA) in RPMI-1640 for 24 h. All transient transfections were performed with Lipofectamine 3000 reagent (Invitrogen, USA) according to manufacturer’s direction.

RNA extraction, complementary DNA (cDNA) synthesis, and quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from tissues or cells using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) as recommended by the supplier. A PARIS Kit (Ambion, Life Technologies, USA) was used to harvest the cytoplasmic and nuclear cell lysates of myoblast, following the manufacturer’s protocol; cDNA synthesis for RNA (mRNA and IncRNA) was carried out using the PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time) (TaKaRa, Otsu, Japan). For mRNA, bulge-Loop™ miRNA qRT-PCR primers specific for miR-15 family and U6 were designed by RiboBio (RiboBio, Guangzhou, China), and ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan) was used to synthesize cDNA. Real-time quantitative PCR (qPCR) reactions were performed on
a Bio-Rad CFX96 Real-Time Detection System using iTaq Universal SYBR Green Supermix Kit (Bio-Rad Laboratories Inc., USA). Data analyses were performed using the 2^{-\Delta \Delta Ct} method as described previously.\textsuperscript{19} Chicken \(\beta\)-actin and U6 were used as internal controls.

**RNA oligonucleotides and plasmids construction**

The gga-miR-15 family mimics (miR-15a, miR-15b-5p, miR-15c-5p, miR-16-5p, and miR-16c-5p), mimic negative control, siRNA target against the \(\text{IRS}1\) gene (si-\(\text{IRS}1\)), siRNA target against the \(\text{IncIRS}1\) gene (si-Inc\(\text{IRS}1\)), and siRNA nonspecific control were designed and synthesized by RiboBio (Guangzhou, China).

The \(\text{IRS}1\) overexpression construct was generated by amplifying the \(\text{IRS}1\) coding sequence, which subsequently integrated into the HindIII/KpnI restriction sites of the pcDNA3.1 overexpression plasmid (named pcDNA3.1-\(\text{IRS}1\)). The full-length sequence of \(\text{IncIRS}1\) was subcloned into the BamHI/XhoI restriction sites of the pcDNA3.1 overexpression plasmid (named pcDNA3.1-Inc\(\text{IRS}1\)). The empty pcDNA3.1 vector was used as control plasmid.

MiR-15 family binding sites in \(\text{IRS}1\) 3’UTR or \(\text{IncIRS}1\) (three binding sites: Site 1 at position 2651–2657 of \(\text{IncIRS}1\); Site 2 at position 3438–3444 of \(\text{IncIRS}1\); and Site 3 at position 3775–3781 of \(\text{IncIRS}1\) ) were amplified by PCR using a cDNA template synthesized from total RNA. Then, the PCR products were subcloned into XhoI/XbaI restriction sites in the pmirGLO dual-luciferase reporter vector to generate the pmirGLO-\(\text{IRS}1\) reporter, pmirGLO-site 1 of \(\text{IncIRS}1\) reporter, pmirGLO-site 2 of \(\text{IncIRS}1\) reporter, and pmirGLO-site 3 of \(\text{IncIRS}1\) reporter.

For identification of the coding ability of \(\text{IncIRS}1\), seven possible Open Reading Frames (ORFs) of \(\text{IncIRS}1\) were amplified and cloned into pSDS-20218 vector (SiDanSai, Shanghai, China). Chicken \(\beta\)-actin gene was subcloned into pSDS-20218 vector as positive control.

**5’ and 3’ rapid amplification of cDNA ends (RACE)**

A SMARTer RACE cDNA Amplification Kit (Clontech, Osaka, Japan) was used to obtain the full-length sequences of \(\text{IncIRS}1\) and \(\text{IRS}1\), following the manufacturer’s instructions. Nested-PCR reactions were performed. The products of the RACE PCR were cloned into the pJET 1.2/blunt cloning vector (CloneJET PCR Cloning Kit; Fermentas, Glen Burnie, MD, USA) and sequenced by Sangon Biotech (Shanghai, China).

**Dual-luciferase reporter assay and RNA immunoprecipitation**

DF-1 cells were seeded in 96-well plates 1 day before transfection and then co-transfected with (I) pmirGLO-\(\text{IRS}1\) reporter, (II) pmirGLO-site 1 of \(\text{IncIRS}1\) reporter, (III) pmirGLO-site 2 of \(\text{IncIRS}1\) reporter, and (IV) pmirGLO-site 3 of \(\text{IncIRS}1\) reporter, and miRNA mimics or mimic NC using Lipofectamine 3000 reagent. After 48 h, luciferase activity analysis was performed using a Fluorescence/Multi-Detection Microplate Reader (BioTek, Winooski, VT, USA) and a Dual-GLO Luciferase Assay System Kit (Promega, USA). The firefly luciferase activities were normalized to Renilla luminescence in each well.

RNA immunoprecipitation used the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) and the anti-Argonaute2 (AGO2) antibody (Abcam, Cambridge, UK) according to the manufacturer’s protocol. After the antibody was recovered by protein A + G beads, qRT-PCR was performed to detect \(\text{IRS}1\), \(\text{IncIRS}1\), and miR-15 family in the precipitates.

**Western blotting**

Myoblast cells were seeded in six-well plates and transfected with overexpression plasmid, siRNA, or miRNA mimics for 48 h. Cells and muscle tissue were harvested, washed with 1× phosphate buffered saline (PBS) and lysed in RIPA lysis buffer. Immunoblotting was performed using standard procedures and various antibodies. The primary antibodies used were anti-\(\text{IRS}1\) (1:1000; catalogue no. ab5603, Abcam, Cambridge, UK), anti-phospho-\(\text{AKT}\) (1:1000; catalogue no. #4040, Cell Signaling Technology, Danvers, MA, USA), anti-\(\text{AKT}\) (1:1000; catalogue no. #9272, Cell Signaling Technology), anti-\(\text{MyHC}\) (1:50; catalogue no. B103, Developmental Studies Hybridoma Bank, Iowa City, Iowa, USA), anti-\(\text{MyoG}\) (1:1000; catalogue no. orb6492, Biorbyt, Cambridge, UK), anti-\(\text{Foxo1}\) (1:1000; catalogue no. 82358, Thermo Fisher Scientific, Meridian Road, IL, USA), anti-phospho-\(\text{Foxo1}\) and anti-phospho-\(\text{Foxo4}\) (1:1000; catalogue no. #9461, Cell Signaling Technology), anti-\(\text{Foxo3}\) (1:1000; catalogue no. NPB2-24579, Novus Biologicals, Littleton, CO, USA), anti-phospho-\(\text{Foxo3}\) (1:1000; catalogue no. bs-3140R, Bios, China), anti-\(\text{Foxo4}\) (1:1000; catalogue no. bs-2766R, Bios), anti-\(\text{Pbx32}/\text{Atrogin-1}\) (1:1000; catalogue no. ab74023, Abcam), and anti-\(\text{GAPDH}\) (1:10 000; catalogue no. MB001H, Bioworld, St Louis Park, MN, USA). The goat anti-mouse IgG (H & L)-HRP (1:10 000; catalogue no. BS12478, Bioworld Technology, Inc.), and goat anti-rabbit IgG (H & L)-HRP (1:10 000; catalogue no. BS13278, Bioworld Technology, Inc.) were used as a secondary antibody.

Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 391–410
DOI: 10.1002/jcsm.12374
Flow cytometric analysis

For the flow cytometry analysis of the cell cycle, myoblast cells were seeded in 12-well plates. When the cells grew to a density of 50% confluence, they were transfected with overexpression plasmid, siRNA, or miRNA mimics. After transfection for 48 h, the cells were collected and fixed overnight in 70% ethanol at 4°C. Subsequently, the fixed cells were stained with 50 μg/mL propidium iodide solution (Sigma Life Science, St. Louis, MO, USA) containing 10 μg/mL RNase A (Takara, Japan) and 0.2% (v/v) Triton X-100 (Sigma Life Science, St. Louis, MO, USA) and then incubated at 37°C in the dark for 30 min. Flow cytometry analysis was performed on a BD Accuri C6 flow cytometer (BD Biosciences, USA), and data were processed using FlowJo7.6 software.

5-Ethylnyl-2'-deoxyuridine (EdU) assay

Myoblast cells were seeded in 12-well plates. When the cells grew to a density of 50% confluence, they were transfected with overexpression plasmid, siRNA, or miRNA mimics. After transfection for 48 h, myoblasts were exposed to 50 μM EdU (RiboBio, China) for 2 h at 37°C. Subsequently, the cells were fixed in 4% paraformaldehyde for 30 min, neutralized using 2 mg/mL glycine solution, and then permeabilized by adding 0.5% Triton X-100. A solution containing EdU (Apollo Reaction Cocktail; RiboBio, China) was added and the cells were incubated at room temperature for 30 min. The nuclear stain Hoechst 33342 was then added, and incubation was continued for another 30 min. A fluorescence microscope (DMI8; Leica, German) was used to capture three randomly selected fields to visualize the number of EdU-stained cells.

Cell counting kit-8 (CCK-8) assay

Primary myoblasts were seeded in 96-well plates and cultured in growth medium. After being transfected, cell proliferation was monitored using a TransDetect CCK (TransGen Biotech, Beijing, China) according to the manufacturer’s protocol. Absorbance was measured using a Model 680 Microplate Reader (Bio-Rad, Hercules, California, USA) by optical density at a wavelength of 450 nm.

Lentiviral vector construction, production, and infection

LncIRS1 knockdown

Lentiviral vectors were constructed to produce lentiviruses expressing short hairpin RNA (shRNA) against LncIRS1. Three shRNA sequences were designed by Shanghai Hanbio Biotechnology Co., Ltd (shRNA-1: 5'-GGTCTCATGTACAACGTAT-3', shRNA-2: 5'-GCACTTAAAGGAAGGCAT-3', shRNA-3: 5'-GCACAACCTAAGACAAAT-3'). These shRNA sequences were subcloned into the pLKO.1 vector between Agel/EcoRI restriction enzyme sites, and high titre lentiviruses were produced. Briefly, the expression vectors were co-transfected with packaging plasmid psPAX2 (Addgene, USA) and envelope plasmid pMD2.G (Addgene, USA) into 293T cells. Infectious particles were harvested at 48 and 72 h after transfection, filtered through 0.45-m pore cellulose acetate filters, concentrated by ultracentrifugation, redissolved in sterile HBSS, aliquoted, and stored at −80°C.

LncIRS1 overexpression

For the construction of LncIRS1-overexpression lentiviral vector, the full-length of LncIRS1 produced from breast muscle cDNA using PCR was subcloned into the BamHI/EcoRI restriction enzyme sites of the lentiviral expression vector (pWPXL). Lentivirus was produced as described earlier.

Lentiviral intramuscular injections

Injections were performed as previously described by Luo with some modifications. Briefly, 1-day-old chicks were received three intramuscular doses (single dose injection started at Days 1, 3, and 5) of lentivirus into the breast muscle at dosage of 1 × 10^8 IU/mL.

Sampling and in vivo validation of lentiviral vectors

Breast muscle samples were taken from pLKO.1-LncIRS1 (n = 15), pLKO.1-control (n = 15), pWPXL-LncIRS1 (n = 15), and pWPXL control (n = 15) group injected chickens 9 days after the initial injection. After removing the breast muscle, 4-mm slices were taken based on designated anatomical markers using standard razor blades. Protein and RNA extraction were performed for Western blot and qPCR analysis.

Histology image analysis

Breast muscle tissues of chicken were obtained from shRNA: pLKO.1-LncIRS1, pLKO-control, and overexpression: pWPXL-LncIRS1, pWPXL-control infected muscle (n = 15/case). On Day 9 after initial dose, the tissues were quickly harvested from all groups and fixed in 10% formalin (10% formalin: 90% PBS). Fixed tissues were paraffin embedded, sectioned and stained with haematoxylin and eosin, and then subjected to image analysis.

Immunofluorescence analysis

The immunofluorescence was performed in myoblast cells cultured in 24-well plates. After transfection for 48 h, cells were fixed in 4% formaldehyde for 20 min and then washed three times with PBS (5 min each). Subsequently, the cells were permeabilized with 0.1% Triton X-100 for 15 min and
blocked with goat serum for 1 h. After overnight incubation at 4°C with anti-MyHC antibody (1:50; B103, Developmental Studies Hybridoma Bank, Iowa City, Iowa, USA), the cells were treated with Dylight 594-conjugated AffiniPure Goat Anti-Mouse IgG (H + L) (1:100; BS10027, Bioworld, USA) and incubated in dark for 1 h. The cell nuclei were visualized using DAPI staining (Beyotime, Jiangsu, China). Images were obtained with a fluorescence microscope (DMi8; Leica, German). The area of cells labelled with anti-MyHC was measured by using ImageJ software (National Institutes of Health), and the total myotube area was calculated as a percentage of the total image area covered by myotubes.

**Statistical analysis**

Each experiment was performed in triplicate. The data are presented as the mean ± standard error of the mean of each set of three independent experiments. Where applicable, the statistical significance of the data was tested using one-sample or paired t-tests. The types of tests and the P-values, when applicable, are indicated in the figure legends.

**Results**

**LncRNA-miRNA-gene interaction network**

There are 239 differentially expressed lncRNAs (DE-lncRNAs) (Figure 1A, Table S1) and 763 differentially expressed genes (Figure 1B, Table S2) were identified with a Benjamini q-value <0.001 and |(fold change)| ≥ 2 as the cut-off. Our previous study has presented the miRNA expression profile between hypertrophic and leaner broilers,21 and 101 differentially expressed miRNAs were identified with a Benjamini q-value of 0.001 as the cut-off (Figure 1C, Table S3). Protein-coding RNAs (genes) and lncRNAs, which share the common MREs, can both compete for binding to miRNAs and regulate each other. In this study, we constructed a putative LncRNA-miRNA-gene crosstalk network involved in skeletal muscle myogenesis. The LncRNA-miRNA-gene crosstalk network construction involved the following three components: interactions between miRNAs and genes, interactions between lncRNAs and miRNAs, and interaction between genes and genes. Firstly, miRNA-gene interaction network contains 378 negatively correlated pairs of miRNA-gene, involving 79 miRNAs and 92 genes (Figure S2, Table S4). Secondly, the target lncRNAs of the 79 differentially expressed miRNAs from the miRNA-gene network were predicted by RNAhybrid. The LncRNA-miRNA interaction network contains 483 negatively correlated pairs of LncRNA-miRNA, involving 173 LncRNAs and 68 miRNAs (Figure S3, Table S5). Thirdly, to narrow the field of the key genes involved in skeletal muscle myogenesis, the genes of miRNA-gene network were used to construct

gene–gene interactions by IPA online software. In IPA analysis, a total of four gene networks were identified (Figure S4). Importantly, one of the four gene–gene networks was involved in cellular compromise, organi
mal injury and abnormalities, and skeletal and muscular disorders (Figure S4c, Table S6), and 16 differentially expressed genes from this network were used for LncRNA-miRNA-gene network construction. Finally, miRNA-gene interactions, LncRNA-miRNA interactions, and gene–gene interactions were integrated to construct possible LncRNA-miRNA-gene network by Cytoscape. The LncRNA-miRNA-gene interaction network contains 733 pairs of LncRNA-miRNA-gene, involving 130 LncRNAs, 31 miRNAs, and 15 genes (Figure 1D). MiR-15 family, including miR-15a, miR-15b-5p, miR-15c-5p, miR-16-5p, and miR-16c-5p are the core component of this interaction network with a large number of genes and LncRNAs connected (Figure 1D). GO and KEGG pathway analyses of the identified genes from the LncRNA-miRNA-gene network revealed that these genes were enriched in transcription regulation-related processes, such as transcription factor activity and regulation of transcription, DNA dependent (Figure S5a). Notably, according to the KEGG analysis, IRS1 gene from LncRNA-miRNA-gene network was enriched in skeletal muscle myogenesis related pathway, such as growth hormone signalling pathway, insulin signalling pathway, and IGF-1 signalling pathway (Figures S5b and S5c). IGF-1 signalling pathway plays a major role in the regulation of skeletal muscle myogenesis (Figure S5d). IRS1 gene is thought to be down-stream of the IGF1 receptor (Figure S5d), and IRS2 null mice have much reduced growth (30–60% of control).22,23 Interestingly, IRS1 is the predicted target gene of miR-15 family which is the core component miRNAs in the LncRNA-miRNA-mRNA network.

**LncIRS1 is up-regulated in hypertrophic broilers**

RNA-seq revealed that 52 lncRNAs were down-regulated and 187 were up-regulated (Table S1) in hypertrophic and leaner broilers. We identified an lncRNA (TCONS_00086268, named LncIRS1) which is upregulated in hypertrophic broiler (Figure 2A and 2B). The 5’ and 3’ ends of LncIRS1 were determined by RACE system (Figure 2C and 2D, Table S7). Predictions of the coding identify of LncIRS1 by the Coding Potential Calculator suggested a low coding potential and low evolutionary conservation consistent with a non-coding RNA (Figure 2E).24 In order to verify this prediction, we analysed the coding ability of seven potential ORFs of LncIRS1. Western blot analysis suggestive that LncIRS1 is an lncRNA with no protein-encoding potential (Figure 2F). The NCBI BLAST indicated that the LncIRS1 was 4623 bp long, located on Chromosome 5 and spanned from 8 080 605 to 8 085 228. We further investigated the subcellular localization of LncIRS1, and the RT-PCR result confirmed that it is an RNA molecule present.
Figure 1  MiR-15 family is the core of lncRNA-miRNA-gene interaction network. (A) Heat map of 239 differentially expressed IncRNAs (DE-IncRNAs) between hypertrophic and leaner broilers, with rows representing IncRNAs and columns representing breast muscle tissues from WRR and XH. (B) Heat map of 763 differentially expressed genes (DEGs) between hypertrophic and leaner broilers, with rows representing mRNAs and columns representing breast muscle tissues from WRR and XH. (C) Heat map of 101 differentially expressed miRNAs (DE-miRNAs) between hypertrophic and leaner broilers, with rows representing miRNAs and columns representing breast muscle tissues from WRR and XH. (D) LncRNA-miRNA-gene interaction network consists of 130 IncRNAs (green circles), 31 miRNAs (pink circles), and 15 genes (blue circles). MiR-15 family, including miR-15a, miR-15b-5p, miR-15c-5p, miR-16-5p, and miR-16c-5p are the core component of this interaction network with a large number of genes and IncRNAs connected. Dashed lines represent the interactions between differentially expressed miRNAs and their corresponding target genes. Solid lines represent the interactions between differentially expressed miRNAs and their corresponding target lncRNAs. LncRNA, long noncoding RNA; miRNA, microRNA; mRNA, messenger RNA.
in the cytoplasm and nucleus (Figure 2G). Moreover, we identified the 5’ and 3’ ends of IRS1 by RACE (Figure 2H and 2I, Table S7).

**LncIRS1 promotes proliferation and differentiation of myoblast**

LncIRS1 was predominantly expressed in breast muscle and heart and followed by liver and leg muscle (Figure 3A). During skeletal muscle development, muscle precursor cells differentiate from the somite. Whole-mount in situ hybridization shows that LncIRS1 is expressed in somite (Figure 3B). This may imply that LncIRS1 plays an important role in myogenesis. Overexpression of LncIRS1 reduced the number of cells that progressed to G0/G1 phase and increased the number of cells that progressed to S phase (Figure 3C) and significantly promoted myoblast proliferation (Figure 3D). Conversely, LncIRS1 knockdown increased cell cycle arrest in the G0/G1 phase (Figure 3C) and significantly reduced myoblast proliferation (Figure 3E). EdU staining also demonstrated that the proliferation rate of LncIRS1 overexpression cells was significantly increased compared with that of the control cells (Figure 3F and 3G). Conversely, proliferation was significantly inhibited...
Figure 3  Skeletal muscle-enriched IncIRS1 promotes myoblast proliferation and differentiation. (A) The RNA expression level of IncIRS1 in 12 different tissues in leaner broilers. Cer, cerebrum; Ceb, cerebellum; Hyp, hypothalamus; Pit, pituitary; Abd, abdominal fat; Brm, breast muscle; Lem, leg muscle; Hea, heart; Liv, liver; Kid, kidney; Spl, spleen; Giz, gizzard. The relative RNA expression of IncIRS1 in different tissues was normalized to Giz. (B) Whole-mount in situ hybridization shows that IncIRS1 is expressed in the forming somites in HH10 chick embryo. Red arrow indicates IncIRS1 expression location. (C) Cell cycle analysis of myoblasts at 48 h after transfection of pcDNA3.1-IncIRS1 and pcDNA3.1 empty plasmid, or si-IncIRS1 and si-NC. (D) CCK-8 assay was performed to assess the effect of IncIRS1 overexpression on myoblast proliferation. (E) CCK-8 assay was performed to assess the effect of IncIRS1 knockdown on myoblast proliferation. (F) EdU and Hoechst (nuclei) staining analysis after transfection of pcDNA3.1-IncIRS1 and pcDNA3.1 empty plasmid, or si-IncIRS1 and si-NC in proliferating myoblast, scale bars are 50 μm. (G) The proliferation rate of myoblast cells transected with pcDNA3.1-IncIRS1 and pcDNA3.1 empty plasmid, or si-IncIRS1 and si-NC. (H, I) Immunofluorescence Myoblast cells transfected with pcDNA3.1-IncIRS1 and pcDNA3.1 empty plasmid, or si-IncIRS1 and si-NC were induced to differentiate for 72 hr then stained with MyHC antibody and DAPI (nuclei). Scale bars are 100 μm. (J, K) Myotube area (%) at 72 h after transfection of pcDNA3.1-IncIRS1 or si-IncIRS1. (L) Knockdown of IncIRS1 decreased the RNA expression level of myoblast cell differentiation associated genes, including MyoD, MyoG, MyHC, and MyoMarker. (M) Knockdown of IncIRS1 decreased the RNA expression level of IGF-1 pathway associated genes, including IGF1, IGF1R, and IGF2R. Results are shown as the mean ± SEM of three independent experiments. Independent sample t-test was used to analysis the statistical differences between groups. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 391–410
DOI: 10.1002/jcsm.12374
after *IncIRS1* knockdown (Figure 3F and 3G). After immunofluorescence staining, we found *IncIRS1* overexpression promoted myoblast differentiation and significantly increased the total areas of myotubes (Figure 3H and 3J), while knockdown of *IncIRS1* reduced myoblast differentiation (Figure 3I and 3K). The expression of myoblast differentiation marker genes (*MyoD, MyHC, MyoG*, and *Myomarker*) and IGF-1 pathway related genes (*IGF1, IGF1R*, and *IGF2R*) were down-regulated in *IncIRS1* knockdown cells compared to control cells (Figure 3L and 3M). Together, the data suggest that *IncIRS1* enriched in muscle and can promote myoblast proliferation and differentiation.

**LnCIRS1 acts as a molecular sponge for miR-15a, miR-15b-5p, and miR-15c-p to regulate IRS1 expression**

*LnCIRS1* locates in both cytoplasm and nucleus (Figure 2G), and it is significantly up-regulated in hypertrophic broiler. We speculated that *IncIRS1* regulate myogenesis by function as a ceRNA. In lncRNA-miRNA-gene network, miR-15 family is the core component of this network, and IRS1 is a target gene of these miRNAs. Interestingly, bioinformatics analysis reveals three or one predicted miRNA binding site in the *IncIRS1* (Figure 4A) or *IRS1* (Figure 4B), respectively. During myoblast proliferation and differentiation, *IRS1* (Figure 4C) and *IncIRS1* (Figure 4D) RNA expression level were upregulated, while the opposite expression pattern was presented in miR-15a (Figure 4E), miR-15b-5p (Figure 4F), and miR-15c-5p (Figure 4G) but not miR-16-5p (Figure 4H) or miR-16c-5p (Figure 4I). Using dual-luciferase reporter gene assays, we validated that miR-15a, miR-15b-5p, and miR-15c-5p can directly interact with the three predicted binding sites of *IncIRS1* (Figure 4J–4L), and these miRNAs can also directly interact with *IRS1* (Figure 4M). To determine whether *IncIRS1* could regulate *IRS1* expression by sequester miRNAs, we cotransfected pmirGLO-*IncIRS1*, miRNAs, and *IncIRS1* overexpression plasmid into DF-1 cells. The luciferase activity increased in response to *IncIRS1* in a dose-dependent manner, suggesting that ectopically expressed *IncIRS1* specifically sequestered miR-15a (Figure 4N), miR-15b-5p (Figure 4O), and miR-15c-5p (Figure 4P), thereby preventing theirs from inhibiting luciferase activity. Overexpression of these miRNAs could simultaneously reduce the expression of *IncIRS1* (Figure 4Q, Figure 5Aa and *IRS1* (Figure 4R, Figure 5Ab). We further performed RNA immunoprecipitation using antibody against AGO2 which is a key component of the RNA-induced silencing complex. As expected, *IncIRS1* (Figure 4S), *IRS1* (Figure 4T), miR-15a, miR-15b-5p, and miR-15c-5p (Figure 4U) were significantly enriched in AGO2 pellet (AGO2 antibody versus IgG). Western blot confirmed that the AGO2 antibody precipitated the AGO2 protein from our cellular extract (Figure 4V). Overexpression of miR-15a, miR-15b-5p, and miR-15c-5p can significantly reduce the protein level of *IRS1* (Figure 4W). Together, these data suggest that *IncIRS1* can regulate the expression of *IRS1* by sequester miR-15a, miR-15b-5p, and miR-15c-5p.

**MiR-15a, miR-15b-5p, and miR-15c-5p suppress myoblast proliferation and differentiation**

We identified miR-15a, miR-15b-5p, and miR-15c-5p are down-regulated in hypertrophic broiler (Figure 5A and 5B). To observe the effects of these miRNAs on myoblast proliferation, we transfected myoblasts with miRNA mimics or miRNA negative control (miR-NC) and then monitored the proliferation status of cells using flow cytometry analysis, CCK-8 assay, and EdU staining. Flow cytometry analysis of the cell cycle revealed that myoblasts transfected with the miR-15a, miR-15b-5p, or miR-15c-5p mimic could arrest myoblasts in the G0/G1 phase (Figure 5C). CCK-8 and EdU staining also demonstrated that the proliferation rate of miR-15a, miR-15b-5p, or miR-15c-5p transfected myoblasts was significantly reduced compared with that of the miR-NC transfected cells (Figure 5D–5F). After immunofluorescence staining, we found miR-15a, miR-15b-5p, or miR-15c-5p overexpression inhibited myoblast differentiation and significantly reduced the total areas of myotubes (Figure 5G and 5H). The expression of IGF-1 pathway related genes (*IGF1*, *IGF1R*, and *IGF2R*) and myoblast differentiation marker genes (*MyoD, MyHC, MyoG*, and *Myomarker*) were down-regulated in miR-15a, miR-15b-5p, or miR-15c-5p overexpression myoblasts compared to miR-NC transfected myoblasts (Figure 5I–5O). Overexpression of miR-15a, miR-15b-5p, or miR-15c-5p reduced the protein expression level of MyoG and MyHC. The kinase AKT is a central component in IGF-1 signaling pathway which plays a major role in the regulation of skeletal muscle growth. As shown in Figure 4W, overexpression of miR-15a, miR-15b-5p, or miR-15c-5p reduced the phosphorylation level of AKT and had no obvious change in total AKT. Together, the data suggest that miR-15a, miR-15b-5p, and miR-15c-5p inhibit myoblast proliferation and differentiation via IGF-1 pathway.

**IRS1 is involved in proliferation and differentiation of myoblast via IGF-1 signalling pathway**

*IRS1* is thought to be downstream of the IGF-1 receptor and associated with mice body weight.6 Here, we identified *IRS1* is upregulated in hypertrophic broiler (Figure 6A and 6B), and predominantly expressed in skeletal muscle (Figure 6C). Whole-mount in situ hybridization shows that *IRS1* is expressed in somite (Figure 6D), which is consistent with *IncIRS1* (Figure 3B). Overexpression of *IRS1* reduced the number of cells that progressed to G0/G1 phase, increased the
Figure 4  LncIRS1 functions as a ceRNA for miR-15a, miR-15b-5p, and miR-15c-5p. (A) Three miR-15 family binding sites in LncIRS1 were identified by RNAhybrid. (B) The miR-15 family binding site in IRS1 was identified by TargetScan. Expression analysis of IRS1 (C), LncIRS1 (D), miR-15a (E), miR-15b-5p (F), miR-15c-5p (G), miR-16-5p (H), and miR-16c-5p (I) during myoblasts proliferation (GM) and differentiation (DM), using qRT-PCR. The dual-luciferase reporter assay verified that Site 1 (position 2651–2657 of LncIRS1) (J), Site 2 (position 3438–3444 of LncIRS1) (K) and Site 3 (position 3775–3781 of LncIRS1) (L) of LncIRS1 could be bound by miR-15a, miR-15b-5p, and miR-15c-5p. (M) The dual-luciferase reporter assay verified that IRS1 could be bound by miR-15a, miR-15b-5p, and miR-15c-5p; pmirGLO-IRS1 or miR-15a (N), miR-15b-5p (O), and miR-15c-5p (P) were transfected into DF-1 cells, together with 0, 25, 50, or 100 ng of sponge plasmid of LncIRS1. Overexpression of miR-15a, miR-15b-5p, or miR-15c-5p decreased the RNA expression level of LncIRS1 (Q) and IRS1 (R). Association of LncIRS1, IRS1, and miR-15a, miR-15b-5p, and miR-15c-5p with AGO2. Cellular lysates from chicken myoblast cells were used for RNA immunoprecipitation with AGO2 antibody. Detection of LncIRS1 (S), IRS1 (T), miR-15a, miR-15b-5p, and miR-15c-5p (U) using qRT-PCR; and detection of AGO2 using IP-Western analysis (V). (W) Overexpression of miR-15a, miR-15b-5p, and miR-15c-5p decreased the protein expression level of IRS1, p-AKT, MyoG, and MyHC. Results are shown as the mean ± SEM of three independent experiments. Independent sample t-test was used to analysis the statistical differences between groups. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. RIP, RNA immunoprecipitation.
Figure 5 MiR-15a, miR-15b-5p, and miR-15c-5p inhibit myoblast proliferation and differentiation. (A) RNA-seq analysis found that miR-15a, miR-15b-5p, and miR-15c-5p were down-regulated in hypertrophic broilers compared with leaner broilers, and this expression pattern was validated by qRT-PCR (B). (C) Cell cycle analysis of myoblasts at 48 h after transfection of miR-15a, miR-15b-5p, miR-15c-5p, and miR-NC. (D) CCK-8 assay was performed to assess the effect of miR-15a, miR-15b-5p, or miR-15c-5p overexpression on myoblast proliferation. (E) EdU and Hoechst (nuclei) staining analysis after transfection of miR-15a, miR-15b-5p, or miR-15c-5p in proliferating myoblast, scale bars are 50 μm. (F) The proliferation rate of myoblast cells transfected with miR-15a, miR-15b-5p, or miR-15c-5p. (G) Myoblast cells transfected with miR-15a, miR-15b-5p, or miR-15c-5p were induced to differentiate for 72 hr then stained with MyHC antibody and DAPI (nuclei). Scale bars are 100 μm. (H) Myotube area (%) at 72 h after transfection of miR-15a, miR-15b-5p, or miR-15c-5p. Overexpression of miR-15a, miR-15b-5p, or miR-15c-5p decreased the RNA expression level of IGF-1 pathway associated genes, including IGF1 (I), IGF1R (J), and IGF2R (K). Overexpression of miR-15a, miR-15b-5p, or miR-15c-5p decreased the RNA expression level of myoblast cell differentiation associated genes, including MyoD (L), MyoG (M), MyHC (N), and MyoMarker (O). Results are shown as the mean ± SEM of three independent experiments. Independent sample t-test was used to analysis the statistical differences between groups. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
**Figure 6** *IRS1* promotes myoblast proliferation and differentiation. (A) RNA-seq analysis found that *IRS1* was up-regulated in hypertrophic broilers, and this expression pattern was validated by qRT-PCR (B). (C) The RNA expression level of *IRS1* in 12 different tissues in leaner broilers and expression was normalized to Gyz. (D) Whole-mount in situ hybridization showed that *IRS1* are expressed in the forming somites in HH10 chick embryo. Red arrow indicates IRS1 expression location. (E) Cell cycle analysis of myoblasts at 48 h after transfection of pcDNA3.1-IRS1 and pcDNA3.1 empty plasmid, or si-IRS1 and si-NC. (F) CCK-8 assay was performed to assess the effect of *IRS1* overexpression on myoblast proliferation. (G) CCK-8 assay was performed to assess the effect of *IRS1* knockout on myoblast proliferation. (H) EdU and Hoechst (nuclei) staining analysis after transfection of pcDNA3.1-IRS1 and pcDNA3.1 empty plasmid, or si-IRS1 and si-NC in proliferating myoblast, scale bars are 50 μm. (I) The proliferation rate of myoblast cells transfected with pcDNA3.1-IRS1 and pcDNA3.1 empty plasmid, or si-IRS1 and si-NC. (J, L) Myoblast cells transfected with pcDNA3.1-IRS1, or si-IRS1 were induced to differentiate for 72 h then stained with MyHC antibody and DAPI (nuclei). Scale bars are 100 μm. (K, M) Myotube area (%) was determined at 72 h after transfection of pcDNA3.1-IRS1 or si-IRS1. (N) Knockdown of *IRS1* decreased the RNA expression level of myoblast cell differentiation associated genes, including MyoD, MyoG, MyHC, and MyoMarker. (O) Knockdown of *IRS1* decreased the RNA expression level of IGF-1 pathway associated genes, including IGF1, IGF1R, and IGF2R. Results are shown as the mean ± SEM of three independent experiments. Independent sample t-test was used to analyse the statistical differences between groups. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
number of cells that progressed to S phase (Figure 6E), and significantly promoted myoblast proliferation (Figure 6F). Conversely, IRS1 knockdown increased cell cycle arrest in the G0/G1 phase (Figure 6E) and significantly reduced myoblast proliferation (Figure 6G). EdU staining also demonstrated that the proliferation rate of IRS1 overexpression cells was significantly increased compared with that of the control cells (Figure 6H and 6I). Conversely, proliferation was significantly inhibited after IRS1 knockdown (Figure 6H and 6I). After immunofluorescence staining, we found IRS1 overexpression promoted myoblast differentiation and significantly increased the total areas of myotubes (Figure 6J and 6K), while knockdown of IRS1 reduced myoblast differentiation (Figure 6L and 6M). The expression of myoblast differentiation marker genes (MyoD, MyHC, MyoG, and Myomarker) and IGF-1 pathway related genes (IGF1, IGF1R, and IGF2R) were down-regulated in IRS1 knockdown cells compared to control cells (Figure 6N and 6O). Together, these data suggest that IRS1 promotes myoblast proliferation and differentiation via IGF-1 pathway.

**LncIRS1 modulated IRS1 expression and promoted myoblast proliferation and differentiation by sponging miR-15a, miR-15b-5p, and miR-15c-p**

To determine whether LncIRS1 functions as a molecular sponge for miR-15a, miR-15b-5p, and miR-15c-p, we performed qPCR analysis of LncIRS1 and IRS1 level in LncIRS1 or IRS1 knockdown myoblast, respectively. Knockdown of LncIRS1 reduce the expression level of IRS1 and simultaneously inhibit IRS1 expression (Figure 7A). Similarly, knockdown of IRS1 reduce the expression level of IRS1 and LncIRS1 (Figure 7B). Furthermore, the rescue assay shown that LncIRS1 overexpression can promote the expression of IRS1 (Figure 7C, Figure S6c). Overexpression of LncIRS1 (OV-LncIRS1) increased the protein level of IRS1 (Figure 7D), as the same effect of IRS1 transfected (OV-IRS1). Overexpression of LncIRS1 increased the phosphorylation level of AKT, which confirmed that LncIRS1 activates the IGF-1 pathway via IRS1 protein. Overexpression of LncIRS1 promotes the myoblast differentiation marker genes (MyoG and MyHC) expression (Figure 7D). The opposite results were observed by knockdown of LncIRS1 or IRS1 (Figure 7E). These data demonstrated that LncIRS1 modulates IRS2 to activate the IGF-1 signalling pathway, affecting myoblast proliferation and differentiation by sponging miR-15a, miR-15b-5p, and miR-15c-p.

**LncIRS1 could rescue skeletal muscle atrophy**

We first investigated the impact of LncIRS1 and miR-15 family on atrophy-related gene expressions in primary myotubes. LncIRS1 overexpression decreased the expression of two atrophy-related genes (atrogenes), Atrogin-1 and MuRF1, at either mRNA levels or protein level of Atrogin-1 compared to the control group (Figure 7F–7H). In contrast, myotubes transfected with LncIRS1 knockdown increased the expression of Atrogin-1 and MuRF1 at either mRNA levels or protein level of Atrogin-1 compared to those transfected with the small interfering RNA negative control (Figure 7F, 7I, and 7J). In addition, overexpression of miR-15a, miR-15b-5p, or miR-15c-5p promotes the protein expression of Atrogin-1 (Figure 7F).

The dexamethasone (synthetic glucocorticoid) has been known to promote protein breakdown and to induce Atrogin-1 and MuRF1 expression in myotube cultures and adult muscles. IGF downstream signalling (AKT-FOXO signalling) has been reported to play a major role in eliciting the myofiber atrophy. We next asked if LncIRS1 rescue muscle atrophy, we performed LncIRS1 overexpression and knockdown during dexamethasone-induced myotube atrophy **in vitro**. We then assessed AKT and FOXO signalling by determining the levels of Foxo1, phosphorylated Foxo1 (p-Foxo1), Foxo3, phosphorylated Foxo3 (p-Foxo3), Foxo4, phosphorylated Foxo4 (p-Foxo4), AKT, phosphorylated AKT (p-AKT), and Atrogin-1 by Western blot analysis. Result showed that protein expression of p-Foxo1, p-Foxo3, p-Foxo4, and p-AKT in dexamethasone-treated myotubes was increased after transfection with LncIRS1 overexpression plasmid (OV-LncIRS1) compared with control (OV-NC) (Figure 8A–8E). The protein expression level of Atrogin-1 was decreased in LncIRS1 overexpression group (Figure 8F). In contrast, the protein expression (p-Foxo1, p-Foxo3, p-Foxo4, and p-AKT) was decreased after interference with si-LncIRS1 (Figure 8G–8K). The protein expression level of Atrogin-1 was increased in si-LncIRS1 group (Figure 8L). Taken together, our data demonstrated that LncIRS1 regulates the expression of atrophy-related genes and further can rescue dexamethasone-induced atrophy in cultured myotubes.

**LncIRS1 controls muscle mass and muscle fibre cross-sectional area**

To test whether LncIRS1 regulates muscle growth **in vivo**, 1-day-old chicks were injected with lentiviral-mediated LncIRS1 overexpression (pWPXL-LncIRS1) and lentiviral-mediated LncIRS1 knockdown (pLKO.1-LncIRS1). Compared with control group (pWPXL-control), the expression level of LncIRS1 or IRS1 gene was significantly higher in pWPXL-LncIRS1 (Figure 9A and 9B). Breast muscle mass (breast muscle weight) and muscle fibre cross-sectional area were both increased in the LncIRS1 overexpression groups compared with those in control groups (Figure 9C–9E), while they were decreased in LncIRS1 knockdown groups (Figure 9F–9J). In addition, we performed Western blot analysis.
Figure 7 LncIRS1 promotes myoblast differentiation via IGF-1 signalling pathway. (A) mRNA expression of LncIRS1 and IRS1 after LncIRS1 knockdown in myoblasts. (B) mRNA expression of LncIRS1 and IRS1 after IRS1 knockdown in myoblasts. (C) Co-expression of miR-15a, miR-15b-5p, or miR-15c-5p with LncIRS1 up-regulated the expression level of IRS1. (D) Overexpression of LncIRS1 or IRS1 increased the protein expression level of IRS1, p-AKT, MyoG, and MyHC. (E) Knockdown of LncIRS1 or IRS1 reduced the protein expression level of IRS1, p-AKT, MyoG, and MyHC. (F) Effect of LncIRS1 overexpression, LncIRS1 knockdown, and miR-15 family on Atrogin-1 protein expression. (G) Effect of LncIRS1 overexpression on MuRF1 RNA expression. (H) Effect of LncIRS1 overexpression on Atrogin-1 RNA expression. (I) Effect of LncIRS1 knockdown on MuRF1 RNA expression in all panels, Myoblast cells transfected with above-indicated chemicals (plasmid DNA, siRNAs, or miRNAs) were induced to differentiate for 48 hr then detected with qRT-PCR or Western blot analysis. Results are shown as the mean ± SEM of three independent experiments. Independent sample t-test was used to analyse the statistical differences between groups. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
for AKT-FOXO signalling in lentiviral-lncIRS1 overexpression and knockdown. The results showed that protein expression of p-Foxo1, p-Foxo3, p-Foxo4, and p-AKT in lncIRS1 overexpression group (pWPXL-lncIRS1) had higher level than did control group (pWPXL-control), while lncIRS1 knockdown group (pLKO.1-lncIRS1) had lower expression level than did the controls (pLKO.1-control) (Figure 9K). Moreover, the protein levels of myogenic markers (MyoG and MyHC) showed similar changes with the parameters of breast muscle mass (Figure 9K). We conclude that lncIRS1 is associated with muscle mass and muscle fibre in vivo.
Discussion

In recent years, studies revealed that lncRNAs containing MREs act as molecular sponges to effectively inhibit miRNA function. Lnc-mg promotes myogenesis by protecting IGF2 transcripts from miR-125b-mediated suppression. Another, lncRNA, FER1L4, play important roles in post-transcriptional regulation in gastric cancer by competing for shared miR-106a-5p. In addition, a circular RNA that contains about 70 MREs with miR-7 was identified. The circular RNA function as efficient miRNA sponge to sequesters miR-7 away from its targets and suppresses its function.

Many studies suggest the important role of lncRNAs in skeletal muscle myogenesis while highlighting the necessity to systematically identify lncRNAs altered in skeletal muscle development. In this study, we constructed the ceRNA network jointed by lncRNAs, miRNAs, and mRNAs. MiR-15a, miR-15b-5p, and miR-15c-5p are the core of this network, and they commonly target with IRS1 which is the key signal transduction gene of IGF-1 signalling pathway. In addition, LncIRS1 controls muscle atrophy by regulating muscle mass and mean muscle fibre in vivo.
we identify a skeletal muscle-enriched IncIRS1 that promotes myogenesis in vitro. In the initial stage of skeletal muscle development, muscle precursor cells differentiate from the somite. In this study, we identified that IRS1 and IncIRS1 were abundantly expressed in somite. During myoblasts proliferation and differentiation, the expression level of IRS1 and IncIRS1 are gradually increased, while the opposite expression pattern of miR-15a, miR-15b-5p, and miR-15c-5p were observed. Overexpression of those miRNAs simultaneously decreased the expression level of IRS1 and IncIRS1. By functioning as a ceRNA, IncIRS1 locks miR-15a, miR-15b-5p, and miR-15c-5p to control the abundance of IRS1 protein and phosphorylation level of AKT. IRS1 is downstream of the IGF-1 receptor and is well known to be principal substrate for IGF-1, which mediated the IGF1-PI3K/AKT signalling pathway. In mice, knockout of IRS1 down-regulated the expression of IGF-1 and led to 40–70% weight loss.

Muscle atrophy is due to a decrease in muscle mass and fibre size. White muscle fibre atrophy occurs under conditions of tough nutritional restriction. In mammals, inactivity and starvation lead to skeletal muscle atrophy. Muscle atrophy also results from a co-morbidity of some common diseases, such as AIDS, congestive heart failure, cancer, chronic obstructive pulmonary disease, renal failure, and severe burns. Atrogin-1 and MuRF1 expressions correlated with loss of muscle protein. In our study, IncIRS1 controls the expression of Atrogin-1 and MuRF1 genes. It has been reported that dexamethasone can increase atrophy-related gene expressions in myotubes, while IGF-I inhibits their expression and blocks dexamethasone effects. The converse of atrophy is hypertrophy, which is induced by an increase in protein synthesis and is characterized by an increase in muscle fibre size. In contrast to atrophy, however, high-rigour marker genes of hypertrophy condition have not been well validated. Skeletal muscle hypertrophy is accompanied by the increased expression of IGF-1. AKT is a central component in IGF1-PI3K/AKT pathway; it controls not only protein synthesis via the kinases mammalian target of rapamycin and glycogen synthase kinase 3β but also protein degradation via the FOXO family transcription factor. In this study, we used myoblast models of hypertrophy for studying the underlying mechanisms that regulate skeletal muscle hypertrophy. Recent studies have shown that the hypertrophy-inducing IGF-1-PI3K/AKT pathway could dominantly block the atrophy-inducing effects of dexamethasone, via AKT mediated phosphorylation and subsequent inhibition of the FOXO family of transcription factors. In this study, we identified that IncIRS1 can activate IGF1-PI3K/AKT pathway by acting as a sponge for miR-15 family to relieve IRS1 expression (Figure 9L). Overexpression of IncIRS1 promotes the expression of IGF-1, activates AKT phosphorylation, and increases skeletal muscle proliferation and total myotube numbers. From a clinical perspective, IncIRS1 can promote the expression of IGF-1 and modulate key atrophy induced genes, such as Atrogin-1 and MuRF1 via the PI3K/AKT pathway, which may be used as a therapeutic target for muscle atrophy.

It has been reported that IncRNA MAR1 played a positive role in skeletal muscle differentiation and growth in vitro and in vivo. To test the function of the IncIRS1 in vivo, we performed IncIRS1 overexpression or knockdown by direct injection of lentiviral particles in breast muscle. In our study, direct injection of overexpression of IncIRS1 lentiviral particles into the breast muscle weakened the muscle atrophy, evidenced by the enhanced breast muscle weight, higher muscle fibre fusion index and higher myogenic marker (MyoG and MyHC) protein expression levels than did the negative control group. However, in the lentiviral-IncIRS1 knockdown experiment, the opposite was true. These results show the therapeutic potential of IncIRS1 in muscle atrophy.

In conclusion, we identified a novel IncIRS1 acts as a sponge for miR-15 family to activate IGF1-PI3K/AKT signalling, resulting in promoting muscle proliferation, differentiation, and muscle mass, which may be used as a potential therapeutic agent for treating muscle atrophy.

Acknowledgements

This work was supported by the Ten-Thousand Talents Program (W03020593), Natural Scientific Foundation of China (31761143014), the Chinese Postdoctoral Science Foundation (2017M622715), Natural Science Foundation of Guangdong Province (2018A030310209), the China Agriculture Research System (CARS-41-G03), and Open Fund of Guangdong Provincial Key Laboratory of Agro-animal Genomics and Molecular Breeding, South China Agricultural University.

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Differential expression analysis of IncRNAs in breast muscle between hypertrophic and leaner broilers.
Table S2. Differential expression analysis of genes in breast muscle between hypertrophic and leaner broilers.
Table S3. Differential expression analysis of miRNAs in breast muscle between hypertrophic and leaner broilers.
Table S4. Differentially expressed miRNAs and theirs corresponding target genes with differential expression in hypertrophic and leaner broilers.
Table S5. Differentially expressed miRNAs and theirs corresponding target IncRNAs with differential expression in
hypertrophic and leaner broilers.

Table S6. Summary of the represented networks generated by IPA analysis.

Table S7. The full length sequences of IncIRS1 and IRS1

Table S8. Information of Primers.

Fig S1 A competing endogenous RNA (ceRNA) hypothesis. LncRNAs and mRNAs, which share the common miRNA response elements (MREs), could influence each other’s levels by competing for a limited pool of miRNA. (a) Upregulation of IncRNA increases cellular concentrations of particular MREs and can result in the derepression of mRNA that contains the same MREs. (b) While downregulation of IncRNA would lead to decreased levels of particular MREs, and, consequently inhibited the expression of mRNA.

Fig S2 miRNA-gene interaction network

Hypertrophic broiler vs. leaner broiler, differentially expressed miRNAs and their corresponding differentially expressed target genes with opposition expression pattern were used to construct a miRNA-gene interaction network. In this network, miRNAs are displayed as pink circles, and miRNA target genes are displayed as blue circles. Dashed lines represent the interactions between differentially expressed miRNAs and their corresponding target genes.

Fig S3 miRNA-lncRNA interaction network

Hypertrophic broiler vs. leaner broiler, differentially expressed miRNAs and their corresponding differentially expressed target IncRNAs with opposition expression pattern were used to construct a miRNA-lncRNA interaction network. In this network, miRNAs are displayed as pink circles, and miRNA target IncRNAs are displayed as green circles. Solid lines represent the interactions between differentially expressed miRNAs and their corresponding target IncRNAs.

Fig S4 Ingenuity Pathway Analysis (IPA) identification of gene networks

IPA online software was used to identify the gene-gene interaction networks, using the genes in the miRNA-gene network as input. (a-d) A total of four major gene networks were identified. Nodes shaded in blue represent the genes from miRNA-gene network are also involved in the IPA interaction network. White nodes represent transcription factors (as opposed to gene from miRNA-gene network) that are associated with the regulation of some of these genes, based on the evidence stored in the IPA knowledgebase. Edges and node are annotated with labels that illustrate the nature of the relationship between the genes and their functions.

Fig S5 GO and pathway analysis of the gene from IncRNA-miRNA-gene network(a) The top 10 enriched terms for three GO categories (biological process, cellular component and molecular function) for the genes belonging to IncRNA-miRNA-gene network. (b) The top 10 enriched pathway for the genes belonging to IncRNA-miRNA-gene network. Pink bars represent the pathway associated with muscle growth. (c) The network between genes and their associated pathway. Yellow oval represent the genes that from IncRNA-miRNA-gene network, while blur bar represent these pathway that they enrich in. (d) Pathway analysis indicates that the genes (IRS1) from IncRNA-miRNA-gene are enriched in the IGF-1 signaling pathway. IRS1 (nodes shaded) function in the IGF-1 signaling pathway.

Fig S6 IncIRS1 acts as a sponge of miR-15a, miR-15b-5p and miR-15c-5p to regulate the expression of IRS1

miR-15a, miR-15b-5p and miR-15c-5p inhibit the RNA expression level of IncIRS1 (a), and simultaneously depress the expression of IRS1 (b). (c) Co-expression of miR-15a, miR-15b-5p or miR-15c-5p, and IncIRS1 upregulate the RNA expression level of IRS1.

Conflict of interest

Z.L., B.C., B.A.A., X.Z., M.Z., P.H., Q.N., and X.Z. declare that they have no conflict of interest.

References

1. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001;4:183–190.
2. Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999;2:201–205.
3. Goldspink DF, Garlick PJ, McNurlan MA. Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem J 1983;210:89–98.
4. Li Z, Ouyang H, Zheng M, Cai B, Han P, Abdalla BA, et al. Integrated analysis of long non-coding RNAs (lncRNAs) and miRNA expression profiles reveals the potential role of LncRNAs in skeletal muscle development of the chicken. Front Physiol 2016;7:687.
5. Dong X, Park S, Lin X, Copps K, Yi X, White MF. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 2006;116:101–114.
6. Tamemoto H, Kodowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182–186.
7. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle 2011;1:4.
8. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet 2014;15:423–437.
9. Guttmann M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012;482:339–346.
10. Fatica A, Bozzone I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014;15:7–21.
11. Caretti G, Schiltz RL, Dilworth FJ, Di Padova M, Zhao P, Ogruuko V, et al. The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell 2006;11:547–560.
12. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011;146:353–358.
13. Ebert MS, Neison JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721–726.
14. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010;465:1033–1038.
15. Cesana M, Cacchiarelli D, Legnini I, Santini T, Strehland S, Cinnamani M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358–369.
16. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 IncRNA antagonizes let-7 microRNAs. Mol Cell 2013;52:221–232.
17. Henrique D, Adam J, Miyat A, Chinnis A, Lewis J, Ish-Horowicz D. Expression of a Delta homolog in prospective neurons of the chick. Nature 1995;375:787–790.
18. Luo W, Wu H, Ye Y, Li Z, Hao S, Kong L, et al. The transient expression of miR-203 and its inhibiting effects on skeletal muscle cell proliferation and differentiation. Cell Death Dis 2014;5:e1347.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 2001;25:402–408.
20. Luo W, Chen J, Li L, Ren X, Cheng T, Lu S, et al. c-Myc inhibits myoblast differentiation and promotes myoblast proliferation and muscle fibre hypertrophy by regulating the expression of its target genes, miRNAs and lncRNAs. Cell Death Differ 2018; https://doi.org/10.1038/s41418-019-0129-0.
21. Ouyang H, He X, Li G, Xu H, Jia X, Nie Q, et al. Deep sequencing analysis of miRNA expression in breast muscle of fast-growing and slow-growing broilers. Int J Mol Sci 2015;16:16242–16262.
22. Baker J, Liu JP, Robertson EJ, Efstathiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73–82.
23. Araki E, Lipes MA, Patti ME, Bruning JC, Haag BR, Johnson RS, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994;372:186–190.
24. Kong L, Zhang Y, Ye ZQ, Liu MQ, Zhao SQ, Wei L, et al. CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res 2007;35:W345–W349.
25. Luo W, Nie Q, Zhang X. MicroRNAs involved in skeletal muscle differentiation. J Genet Genomics 2013;40:107–116.
26. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704–1708.
27. Wang L, Luo GJ, Wang JJ, Hasselgren PO. Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured l6 myotubes. Shock 1998;10:298–306.
28. Levine S, Biswas C, Dierov J, Barsotti R, Shragger JB, Nguyen T, et al. decreased proteolysis, myosin depletion, and atrophic AKT-FOXO signaling in human diabetic muscle. Science 2001;294:1704–1708.
29. Wang L, Luo GJ, Wang JJ, Hasselgren PO. Dexamethasone stimulates proteasome-dependent and calcium-dependent proteolysis in cultured l6 myotubes. Shock 1998;10:298–306.
30. Levine S, Biswas C, Dierov J, Barsotti R, Shragger JB, Nguyen T, et al. decreased proteolysis, myosin depletion, and atrophic AKT-FOXO signaling in human diabetic muscle. Science 2001;294:1704–1708.
31. Levine S, Biswas C, Dierov J, Barsotti R, Shragger JB, Nguyen T, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704–1708.
32. Xie T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, et al. Long noncoding RNA-associated competing endogenous RNAs in gastric cancer. Sci Rep 2014;4:6088.
33. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013;495:333–338.
34. Maddock DM, Burton MP. Some effects of starvation on the lipid and skeletal muscle layers of the winter flounder, Pleuronectes americanus. Can J Zool 1994;72:1672–1679.
35. Fuster G, Busquets S, Almendro V, López-Soriano FJ, Aragilés JM. Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy? Clin Nutr 2007;26:658–661.
36. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol 1990;259:E89–E95.
37. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase Atrogin-1 and decrease skeletal muscle atrophy. Cell 2004;117:399–412.
38. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395–403.
39. Zhang ZK, Li J, Guan D, Liang C, Zhou Z, Liu J, et al. A newly identified IncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. J Cachexia Sarcopenia Muscle 2018;9:613–626.
40. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. J Cachexia Sarcopenia Muscle 2017;8:1081–1083.